Results 61 to 70 of about 12,682 (143)

The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities

MedComm, Volume 7, Issue 3, March 2026.
Diverse diseases converge on NLRP3. We depict a discovery‐to‐clinic track: high‐throughput/phenotypic screens, structure‐guided design, and modality innovation (allosteric inhibitors, interface blockers, degraders) deliver third‐generation, disease‐tailored NLRP3 control.
Chan Zou, Shilong Jiang, Hui Li, Kai Zhao, Dongshen Cao, Guoping Yang   +5 more
wiley   +1 more source

Fenofibrate-promoted hepatomegaly and liver regeneration are PPARα-dependent and partially related to the YAP pathway

Acta Pharmaceutica Sinica B
Fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, is widely prescribed for hyperlipidemia management. Recent studies also showed that it has therapeutic potential in various liver diseases.
Shicheng Fan, Yue Gao, Pengfei Zhao, Guomin Xie, Yanying Zhou, Xiao Yang, Xuan Li, Shuaishuai Zhang, Frank J. Gonzalez, Aijuan Qu, Min Huang, Huichang Bi   +11 more
doaj   +1 more source

Temperature‐Gradient Transcriptomic Atlas Reveals the PPAR Signaling Pathway Dysfunction in Heat Stroke Induced Liver Injury

FASEB BioAdvances, Volume 8, Issue 3, March 2026.
Gradient‐ Temperature Atlas Uncovers Hepatic PPAR Metabolic Reprogramming. We present a murine heat‐stroke atlas (40°C–43°C) and identify PPAR‐linked lipid reprogramming as the primary mechanistic signature of temperature‐dependent liver injury, providing time‐resolved molecular targets for mechanism‐based therapies.
Ying Zhu, Wanlin Liu, Chunyuan Yang, Teng Ma, Mingfei Han, Jinxu Zhang, Yunping Zhu, Jie Ma   +7 more
wiley   +1 more source

Reduced Serum Urate Concentrations Despite Unchanged Allopurinol Dosing in Gout Patients Commenced on Dialysis: A Retrospective Chart Review

Nephrology, Volume 31, Issue 3, March 2026.
The study investigated allopurinol dosing practises and serum urate concentrations in gout patients with kidney failure following commencing dialysis. Results showed allopurinol dose was most commonly 100 mg, unadjusted upon commencing dialysis. However, serum urate concentrations significantly declined as patients commenced dialysis with more than 50%
Noha Kamel, Ronald Castelino, Daniel Wright, Kamal Sud, Surjit Tarafdar, Stephen Hughes, Sophie Stocker   +6 more
wiley   +1 more source

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study[S]

Journal of Lipid Research, 2010
Hypertriglyceridemia, defined as a triglyceride measurement > 150 mg/dl, occurs in up to 34% of adults. Fenofibrate is a commonly used drug to treat hypertriglyceridemia, but response to fenofibrate varies considerably among individuals.
Mary K. Wojczynski, Guimin Gao, Ingrid Borecki, Paul N. Hopkins, Laurence Parnell, Chao-Qiang Lai, Jose M. Ordovas, B. Hong Chung, Donna K. Arnett   +8 more
doaj   +1 more source

Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension

PPAR Research, 2011
Peroxisome proliferator-activated receptor-alpha (PPAR-α) activation by fenofibrate reduces blood pressure and sodium retention during DOCA-salt hypertension. PPAR-α activation reduces the expression of inflammatory cytokines, such as interleukin-6 (IL-
Dexter L. Lee, Justin L. Wilson, Rong Duan, Tamaro Hudson, Ahmed El-Marakby   +4 more
doaj   +1 more source

Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide

International Journal of Nanomedicine, 2012
Kwang-Ho Cha,1,3 Kyung-Jin Cho,3 Min-Soo Kim,4 Jeong-Soo Kim,3 Hee Jun Park,1,3 Junsung Park,1,3 Wonkyung Cho,1,3 Jeong-Sook Park,3 Sung-Joo Hwang1,21Yonsei Institute of Pharmaceutical Sciences, 2College of Pharmacy, Yonsei University, Incheon, Republic ...
Cha KH, Cho KJ, Kim MS, Kim JS, Park HJ, Park J, Cho W, Park JS, Hwang SJ   +8 more
doaj  

Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes

Cardiovascular Diabetology
Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease.
Jiwon Park, Hangyul Song, Shinje Moon, Yumin Kim, Sungsoo Cho, Kyungdo Han, Cheol-Young Park, Sung Woo Cho, Chang-Myung Oh   +8 more
doaj   +1 more source

Fenofibrate ameliorated atorvastatin and piperine-induced ROS mediated reproductive toxicity in male Wistar rats

Toxicology Reports
Atorvastatin and fenofibrate are well-known lipid-lowering drugs. Atorvastatin acts by reducing the production of cholesterol through the inhibition of the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG Co-A reductase) enzyme, whereas fenofibrate ...
Sanjib Ghosh, Sweata Sarkar, Maharaj Biswas   +2 more
doaj   +1 more source

Fenofibrate targets PPARα-CPT1C axis to reverse aging by regulating lipid metabolism and mitochondrial function

Pharmacological Research
Aging poses a growing global health burden, creating an urgent need for effective interventions. This study reveals that fenofibrate, a clinically approved drug for hyperlipidemia, exerts significant anti-aging effects by targeting fundamental aging ...
Yanying Zhou, Yixin Chen, Linlin Zhu, Huilin Li, Yue Gao, Tu Xian, Pengfei Zhao, Shicheng Fan, Núria Casals, Min Huang, Huichang Bi   +10 more
doaj   +1 more source